期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 46, 期 -, 页码 741-760出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST20170531
关键词
-
资金
- Castilla-Leon Government [CSI049U16]
- Spanish Ministry of Economy and Competitiveness [SAF2015-64556-R]
- Worldwide Cancer Research [14-1248]
- Ramon Areces Foundation
- Spanish Society against Cancer [GC16173472GARC]
- Spanish national government
- Spanish regional government
- European Regional Development Fund
RHO GTPases have been traditionally associated with protumorigenic functions. While this paradigm is still valid in many cases, recent data have unexpectedly revealed that RHO proteins can also play tumor suppressor roles. RHO signaling elements can also promote both pro- and antitumorigenic effects using GTPase-independent mechanisms, thus giving an extra layer of complexity to the role of these proteins in cancer. Consistent with these variegated roles, both gain- and loss-of-function mutations in RHO pathway genes have been found in cancer patients. Collectively, these observations challenge long-held functional archetypes for RHO proteins in both normal and cancer cells. In this review, I will summarize these data and discuss new questions arising from them such as the functional and clinical relevance of the mutations found in patients, the mechanistic orchestration of those antagonistic functions in tumors, and the pros and cons that these results represent for the development of RHO-based anticancer drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据